AmphiArc2 Off1

General Information


DRACP ID  DRACP02770

Peptide Name   AmphiArc2 Off1

Sequence  RVFKKFHPIYHRVWRLWGHL

Sequence Length  20

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane-targeted



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MCF-7 Invasive breast carcinoma of no special type Carcinoma EC50=27.4 ± 0.5 µM MTT assay 24 h 1
A549 Lung adenocarcinoma Carcinoma EC50=49 ± 2 µM MTT assay 24 h 1

Hemolytic Activity  Human erythrocytes: HC50>200 µM

Normal (non-cancerous) Cytotoxicity  HDMEC: EC50=56 ± 7 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02770

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C132H191N39O22

Absent amino acids  ACDEMNQST

Common amino acids  HR

Mass  301529

Pl  12.25

Basic residues  8

Acidic residues  0

Hydrophobic residues  9

Net charge  8

Boman Index  -3558

Hydrophobicity  -49.5

Aliphatic Index  87.5

Half Life 
  Mammalian: 1 hour
  Yeast: 2 min
  E.coli: 2 min

Extinction Coefficient cystines  12490

Absorbance 280nm  657.37

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 31375699

Title  In silico design and optimization of selective membranolytic anticancer peptides

Doi 10.1038/s41598-019-47568-9

Year  2019

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_16595

DRACP is developed by Dr.Zheng's team.